Following the exits of its chief executive officer in March and chief operating officer and chief financial officer in May, Endo Health Solutions Inc. (ENDP) is shaking things up some more in a bid to save about $325 million each year in operating expenses. Further, Endo said it’s exploring strategic alternatives for its HealthTronics business, which provides urological products and services, and its branded pharmaceutical discovery platform, while trimming its full-year outlook.
The HealthTronics segment is the smallest revenue contributor for Endo, generating $50.03 million in the three months ended March 31. Endo acquired HealthTronics in 2010 for $223 million.
Endo’s discovery platform contains several drugs in development for different indications, but no details were provided on plans of action related to restructuring initiatives.
The Malvern, Pennsylvania-based healthcare company Tuesday evening outlined its restructuring plans that are being set in motion after a “comprehensive assessment of Endo’s strengths and challenges, its cost structure and execution capabilities and its most promising opportunities to drive future cash flow and earnings growth.”
According to QuoteMedia, Endo has 4,629 employees; meaning about 700 people will be laid-off.
Endo said it is expecting about $150 million of the $325 million in reductions to be realized this year with the remainder realized by mid-2014. The company expects to record charges of about $60 million for the restructuring, mostly because of severance payments.
In May, the company set its full-year guidance at earnings per share in the range of $4.40 to $4.70 and revenue in the range of $2.8 billion and $2.95 billion. On Wednesday, that outlook was lowered to EPS between $4.10 and $4.40 on sales between $2.65 billion and $2.8 billion.
The profit forecast is still in the range of Wall Street expectations at $4.27 per share. Sales were anticipated at $2.8 billion.
Rajiv De Silva, chief executive of Endo, said the changes being implemented “are designed to bring sharper focus to Endo's strategic growth priorities while right-sizing the organization.” De Silva, who left his position as president of Valeant Pharmaceuticals and replaced Dave Holveck as top executive at Endo in March, added, “We believe these actions will leave Endo with the right cost structure, leadership and execution capabilities to drive sustainable cash flow and earnings growth over time.”
Endo has been facing some hurdles, although it turned a profit in the first quarter (versus a net loss in the year earlier quarter) as revenue dropped because of lower sales of its painkillers Lidoderm and Opana ER. In August 2012, the FDA approved Actavis,’ Inc.’s (ACT) generic of Lidoderm., although sales cannot start until September. Endo has fought to block the generic from going to market, but has been unsuccessful, including the FDA denying their petition in May. Further, the FDA has refused to approve Aveed, an injectable testosterone drug of Endo, on three occasions.
Shares of ENDP have risen sharply in 2013, climbing about 43 percent through Wednesday’s close at $35.96. Traders don’t seem too be interpreting the job cuts as weakness as shares are up modestly in Thursday pre-market activity at $36.20.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer